MGRX
Mangoceuticals, Inc.
$0.36
-0.01 (-3.59%)
At close · Jul 8
Going-concern doubt
— flagged May 19, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the ability of the Company to continue as a going concern. Unless management is able to obtain additional financing, it is unlikely that the Company will be able to meet its funding requirements during the 12 months from date of issuance of this filing.”View the 10-Q filed May 19, 2026
Market Cap
$6.37M
Shares
17,167,422
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.36
Open$0.37
Day$0.34–0.38
52W$0.16–2.75
Avg vol 30d1.8M
Short int269K · 1.6% float · 1.0d
Short vol20%
DataMar 2023–Jul 2026
Filing10-Q · May 19
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−59%
below
Price vs 50-day avg
−6%
below
RSI (14)
47
neutral
MACD trend
Positive
52-week position
8%
near low
Momentum
relative strength
1-month return
−1%
trailing
6-month return
−49%
trailing
YTD return
−51%
this year
Relative strength
−57%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.57% of float · ▲ +16.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
18 holders — near 1-yr high, broad support
Squeeze score
38
low risk · 0–100
Fundamentals
Revenue growth
−26%
Y/Y
Gross margin
55%
contracting
EPS growth
+55%
Y/Y
Free cash flow
$-5.9M
Balance sheet
$1.5M
net cash
Quant / Vol
risk profile
Volatility
186%
annualized · 1-yr
Max drawdown
−94%
past year
ATR
14.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 19, 2026
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−59%
Bearish
Price vs 50-day avg
−6%
Bearish
RSI (14)
47
Neutral
MACD trend
Positive
Bullish
52-week position
8%
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.57% of float · ▲ +16.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
18 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $0
Now $0 · 8%
52-wk high $3
vs 200-day avg -59%
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MGRX
this stock
Mangoceuticals, Inc.
|
$6.37M | -51.4% | -26.0% | — | 1.6% |
|
VEEV
Veeva Systems Inc
|
$30.82B | -15.7% | +28.1% | 33.6 | 4.6% |
|
PMDIY
Pro Medicus Ltd./ADR
|
$15.67B | -9.4% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$13.88B | +88.3% | -0.4% | 51.1 | 4.8% |
|
TEM
Tempus AI, Inc.
|
$11.04B | -3.0% | +65.8% | — | 21.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MGRX | -5.4% | -1.0% | -49.1% | -5.4% | -51.4% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | -5.2% | -1.8% | -56.5% | -5.2% | -60.7% |